RT Journal Article
SR Electronic
T1 Conservative Management of Alloimmune Hemolysis and Cholestasis With Extreme Laboratory Abnormalities
JF Pediatrics
JO Pediatrics
FD American Academy of Pediatrics
SP e20193367
DO 10.1542/peds.2019-3367
VO 147
IS 2
A1 Kotch, Chelsea
A1 Friedman, David F.
A1 Wilkins, Benjamin J.
A1 Samelson-Jones, Benjamin J.
YR 2021
UL http://pediatrics.aappublications.org/content/147/2/e20193367.abstract
AB Alloimmune hemolytic disease of the fetus or newborn (HDFN) is a rare cause of neonatal cholestasis. HDFN-associated cholestasis has most often been reported secondary to anti-D alloimmunization. In utero transfusions are also an identified risk factor. A variety of diagnostic and therapeutic strategies have been described, mostly in case reports. Here, we report 2 cases of HDFN-associated cholestasis that were notable for extreme laboratory abnormalities including a peak ferritin of 24 700 ng/mL and a peak alanine aminotransferase of 1406 U/L (33.5-fold upper limit of normal). One case was due to alloimmunization other than anti-D. These cases help define the range of laboratory derangements that are consistent with HDFN-associated cholestasis, including extreme hyperferritinemia. Although in a number of cases, researchers have reported the use of iron chelation in these infants, herein, we describe successful management without iron chelation.